Abstract Background In December 2019, a novel coronavirus disease (COVID-19) emerged
in Wuhan, China, with an incredible contagion rate. However, the vertical transmission of …

Background: Increasing clinical evidence suggests that people with severe mental illness
(SMI), including schizophrenia spectrum disorders, bipolar disorder (BD), and major …

Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the
cause of the ongoing global pandemic known as COVID-19. Based on the potential antiviral …

In addition to respiratory complications produced by SARS‐CoV‐2, accumulating evidence
suggests that some neurological symptoms are associated with the disease caused by this …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a causative virus in the
development of coronavirus disease 2019 (Covid-19) pandemic. Respiratory manifestations …

An understanding of the pathological inflammatory mechanisms involved in SARS-CoV-2
virus infection is necessary in order to discover new molecular pharmacological targets for …

There is controversial literature about the effects of the interleukin‐2 (IL‐2) cytokine family in
COVID‐19 pathogenesis and immunity. So we aimed to identify the potential in the role of …

The portfolio of SARS-CoV-2 small molecule drugs is currently limited to a handful that are
either approved (remdesivir), emergency approved (dexamethasone, baricitinib, paxlovid …

In the beginning of the third year of the fight against COVID-19, the virus remains at least still
one step ahead in the pandemic “war”. The key reasons are evolving lineages and …

Abstract Coronavirus disease 2019 (COVID-19) is a global pandemic caused by SARS-CoV-
2 infection. Patients with severe COVID-19 exhibit robust induction of proinflammatory …